TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive Biological Modifiers Journal Objects To NEJ Policy, Says It Will OK Clinical Data Release April 26, 1985